Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dual HER2 Blockade in Non-Small Cell Lung Cancer Harboring a HER2 Mutation.

Connecticut medicine - 1 Oct 2015

Mar Nataliya, Vredenburgh James J

Abstract excerpt

Identification of targetable oncogenic mutations in non-small cell lung cancer (NSCLC) has been a major advance in cancer treatment. Laboratory techniques to assess human epidermal growth factor receptor 2 (HER2) positivity in NSCLC include immunohistochemistry (IHC) for protein overexpression, fluorescent in situ hybridization (FISH) for gene amplification, and next generation sequencing (NGS) for HER2 gene...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cerebellar Neoplasms

Share to DNA Copy Number Variations

Share to Immunohistochemistry

Share to In Situ Hybridization, Fluorescence

Share to Liver Neoplasms

Share to Receptor, ErbB-2

Source

Identifiers

PMID: 26630704

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dual HER2 Blockade in Non-Small Cell Lung Cancer Harboring a HER2 Mutation.PMID 26630704Read ↗

Targeting HER2 in the treatment of non-small cell lung cancer.Semantic proximity Read ↗

Management of HER2 alterations in non-small cell lung cancer - The past, present, and future.Semantic proximity Read ↗

HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations.Semantic proximity Read ↗

Clinicopathologic and Molecular Characteristics of HER2 (ERBB2)-Altered Non-Small Cell Lung Cancer: Implications for Precision Medicine.Semantic proximity Read ↗

HER2 Alterations in Non-Small Cell Lung Cancer: Emerging Perspectives on the Therapeutic Landscape.Semantic proximity Read ↗

HER2 in Non-Small Cell Lung Cancer: A Review of Emerging TherapiesSemantic proximity Read ↗

HER2 Therapies in Non-Small Cell Lung Cancer (NSCLC).Semantic proximity Read ↗

[Advances in Diagnosis and Treatment of HER2-positive Non-small Cell Lung Cancer].Semantic proximity Read ↗

HER2 and lung cancer.Semantic proximity Read ↗

Recent Advances in the Development and Clinical Use of HER2 Inhibitors in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

The force of HER2 - A druggable target in NSCLC?Semantic proximity Read ↗

HER2 Mutations in Non-Small Cell Lung Cancer: A Herculean Effort to Hit the Target.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.